Liver Diseases  >>  Incivek (telaprevir)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

17 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
NCT01581138: VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

Completed
2b
64
US
VX-222, telaprevir, VX-950, INCIVEK, INCIVO, TELAVIC, ribavirin, Copegus
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C Virus
06/13
12/13
NCT01516918 / 2011-004150-26: A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

Completed
2b
103
US, Canada, Europe
VX-222, telaprevir, Incivek, VX-950, Incivo, ribavirin, Copegus, peginterferon-alfa-2a, Pegasys
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C Virus
09/13
12/13
NCT00561015 / 2007-002920-14: A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection

Completed
2a
52
Europe
Telaprevir, VX-950, Peg-IFN-alfa-2a + Ribavirin (Standard Treatment), Placebo
Tibotec BVBA
Hepatitis C, Chronic
06/08
05/09
NCT00528528 / 2007-001044-44: An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Completed
2a
166
Europe
Telaprevir, Peg-IFN-alfa-2a, Peg-IFN-alfa-2b, Ribavirin (RBV) tablet, Ribavirin (RBV) capsule
Tibotec BVBA
Chronic Hepatitis C
07/09
08/09
NCT00580801 / 2007-005281-12: An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection

Checkmark
Jun 2014 - Jun 2014: 
Checkmark
Jun 2013 - Jun 2013: 
Completed
2a
24
Europe, RoW
Telaprevir, Pegylated-interferon-alfa-2a, Placebo, Ribavirin
Tibotec BVBA
Hepatitis C
01/10
01/10
NCT00983853 / 2008-007995-81: Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Checkmark Data
May 2013 - May 2013: Data
Checkmark P2 data
Mar 2012 - Mar 2012: P2 data
Checkmark Data
More
Completed
2a
62
US, Europe
telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose)
Vertex Pharmaceuticals Incorporated, Tibotec Pharmaceutical Limited
Hepatitis C, HIV Infections
03/12
 
NCT00262483: Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

Completed
2
12
US
VX-950, ribavirin, peginterferon alfa-2a
Vertex Pharmaceuticals Incorporated
Hepatitis C
 
04/06
NCT00372385 / 2006-000828-14: Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Completed
2
334
Europe
Ribavirin, Pegylated Interferon Alfa 2a, Placebo, Telaprevir, VX-950
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
05/08
06/08
NCT00420784 / 2006-004665-33: A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Checkmark EASL 2013: PROVE3
Apr 2013 - Apr 2013: EASL 2013: PROVE3
Completed
2
465
US, Canada, Europe
Telaprevir, VX-950, Ribavirin, RBV, Pegylated Interferon Alfa 2a, Peg-IFN-alfa-2a, Matching Placebo
Vertex Pharmaceuticals Incorporated
Hepatitis C
12/08
04/09
NCT00892697: Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)

Completed
2
15
US
Telaprevir, Peginterferon alfa-2a, Ribavirin
Weill Medical College of Cornell University, Vertex Pharmaceuticals Incorporated
Hepatitis C
12/12
12/12
TelapreVIH, NCT01332955: Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen

Checkmark ANRS HC26 TelapreVIH
Aug 2014 - Aug 2014: ANRS HC26 TelapreVIH
Checkmark CROI 2014: ANRS HC26 TelapreVIH
Mar 2014 - Mar 2014: CROI 2014: ANRS HC26 TelapreVIH
Checkmark CROI 2014: ANRS HC26 TelapreVIH
More
Completed
2
70
Europe
Telaprevir, VX-950, pegIFN alfa-2a, peginterferon alfa-2a, Pegasys®, Ribavirin, Copegus®, Rebetol®
ANRS, Emerging Infectious Diseases, Janssen-Cilag Ltd.
Hepatitis C, Chronic, HIV Infection
09/13
09/13
NCT01482390 / 2011-002715-28: A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

Completed
2
80
US, Canada, Europe
Ribavirin, Copegus, Mericitabine, Peginterferon Alfa-2a, Pegasys, Placebo, Telaprevir
Hoffmann-La Roche
Hepatitis C
01/14
01/14
NCT01355289 / 2010-024479-20: Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

Completed
2
65
US
Avatrombopag, E5501, Avatrombopag maleate, Placebo, Pegylated interferon (PEG-IFN), Telaprevir, Incivek, Incivo, Ribavirin, Virazole, Rebetol, Copegus, Ribasphere, Moderiba dose pack, Moderiba
Eisai Inc.
Thrombocytopenia
02/14
05/14
NCT01467505: An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

Terminated
2
61
US, Canada
Telaprevir, VX-950, Ribavirin, Copegus®, RBV, Pegylated Interferon Alfa-2a, Pegasys®, Peg-IFN-alfa-2a, Immunosuppressant Regimen
Vertex Pharmaceuticals Incorporated
Hepatitis C
04/14
04/14
STEADFAST, NCT01994486: Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1

Completed
2
20
US
Telaprevir and Sofosbuvir, TVR, SOF
University of Florida, Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
04/14
09/14
NCT01648140: Dose Ranging of GSK2336805 in Combination Therapy

Completed
2
286
US, Europe
GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a, Pegasys, Ribavirin, Ribasphere, Telaprevir, Incivek (United States), Incivo (European Union)
GlaxoSmithKline, PPD
Hepatitis C, Chronic
07/14
07/14
NCT01701063 / 2011-004564-30: An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

Terminated
1/2
42
US, Europe
Telaprevir, Peginterferon alfa-2b, PegIntron®, Ribavirin, Rebetol®
Vertex Pharmaceuticals Incorporated, Janssen Pharmaceuticals
Hepatitis C
04/15
04/15

Download Options